Hybrid Exosome-Bilosome Oxygen Nanobubbles for Liver Fibrosis Attenuation: Antifibrotic Efficacy Investigation in Multilineage Spheroid Platform
- 30 September 2026
- journal article
- Published by American Chemical Society (ACS) in ACS Nano Medicine
- Vol. 1 (10) , 2644-2657
Abstract
Liver fibrosis refers to the excessive buildup of scar tissue in the liver, which can lead to cirrhosis and hepatocellular carcinoma. It often presents with a hypoxic hepatic microenvironment and elevated oxidative stress. In this work, we present a hybrid Exosome-Bilosome Oxygen-encapsulating Nanobubble (EBON) with antifibrotic properties that has the potential to protect the liver from localized hypoxia and oxidative stress-induced hepatic damage. Grapefruit-derived exosome-like vesicles utilized here may contribute to the therapeutic potential of the EBON formulation by delivering antioxidant, anti-inflammatory, and antifibrotic cargo, alongside oxygen. EBON has a sub-50 nm size with an oxygen loading capacity of about 50 mg/L and a shelf life of half a year. EBON has demonstrated excellent protection against cellular hypoxia, reactive oxygen species, and superoxide-induced damage in LX-2 and HepG2 cell lines. Additionally, EBON has shown a significant antifibrotic effect in palmitic acid and oleic acid-induced lipotoxicity and oxidative stress-mediated fibrosis model in LX-2/HepG2 multilineage hepatic spheroids. RT-qPCR results confirmed suppression of hypoxia (HIF-1α, VEGF-A), oxidative stress (Nrf2), and pro-fibrotic signaling (α-SMA, TGF-β1, and COL1A1) associated genes in the in vitro hepatic spheroid model. Additionally, the safety profile of EBON has been established in a 14-day murine oral gavage model, validating short-term oral tolerability. We propose that the hybrid Exosome-Bilosome Oxygen encapsulating Nanobubble reported here is a proof-of-concept platform with antifibrotic potential for addressing hypoxia associated with liver fibrosis.Keywords
Funding Information
- Graduate Program in Physics at UNIFAL-MG (1R21EY035371-01)
- Graduate Program in Physics at UNIFAL-MG (2236857)
This publication has 41 references indexed in Scilit:
- HBOT alleviates diet-induced MASH by reprograming gut microbiota and liver metabolism in miceFree Radical Biology and Medicine, 2025
- Advancements in plant-derived exosome-like vesicles: Versatile bioactive carriers for targeted drug delivery systemsJournal of Pharmaceutical Analysis, 2025
- Hypoxia-inducible factor-1 alpha (HIF-1α) inhibitor AMSP-30 m attenuates CCl4-induced liver fibrosis in mice by inhibiting the sonic hedgehog pathwayChemico-Biological Interactions, 2025
- Transepithelial transport of nanoparticles in oral drug delivery: From the perspective of surface and holistic property modulationActa Pharmaceutica Sinica B, 2024
- Safety of surfactant excipients in oral drug formulationsAdvanced Drug Delivery Reviews, 2023
- Targeting collagen homeostasis for the treatment of liver fibrosis: Opportunities and challengesBiochemical Pharmacology, 2023
- Recent advances of Pluronic-based copolymers functionalization in biomedical applicationsMaterials Science and Engineering: C, 2023
- Triglycerides of medium-chain fatty acids: a concise reviewJournal of Food Science and Technology, 2022
- Nrf2 promotes the development of fibrosis and tumorigenesis in mice with defective hepatic autophagyJournal of Hepatology, 2014
- Alpha-SMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver transplantationDigestive and Liver Disease, 2005